title: A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines.
abstract: Therapeutic monoclonal antibodies (mAbs) possess a high degree of heterogeneity associated with the cell expression system employed in manufacturing, most notably glycosylation. Traditional immunoassay formats used to quantify therapeutic mAbs are unable to discriminate between different glycosylation patterns that may exist on the same protein amino acid sequence. Mass spectrometry provides a technique to distinguish specific glycosylation patterns of the therapeutic antibody within the same sample, thereby allowing for simultaneous quantification of the same mAb with different glycosylation patterns. Here we demonstrate a two-step approach to successfully differentiate and quantify serum mixtures of a recombinant therapeutic mAb produced in two different host cell lines (CHO vs. Sp2/0) with distinct glycosylation profiles. Glycosylation analysis of the therapeutic mAb, CNTO 328 (siltuximab), was accomplished through sample pretreatment consisting of immunoaffinity purification (IAP) and enrichment, followed by liquid chromatography (LC) and mass spectrometry (MS). LC-MS analysis was used to determine the percentage of CNTO 328 in the sample derived from either cell line based on the N-linked G1F oligosaccharide on the mAb. The relative amount of G1F derived from each cell line was compared with ratios of CNTO 328 reference standards prepared in buffer. Glycoform ratios were converted to concentrations using an immunoassay measuring total CNTO 328 that does not distinguish between the different glycoforms. Validation of the IAP/LC-MS method included intra-run and inter-run variability, method sensitivity and freeze-thaw stability. The method was accurate (%bias range = -7.30-13.68%) and reproducible (%CV range = 1.49-10.81%) with a LOQ of 2.5 μg/mL.
authors.affiliation: Biologics Clinical Pharmacology, Janssen Research & Development, LLC, Radnor, PA, USA. BGeist@its.jnj.com
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Geist
authors.forename: Darryl
authors.initials: D
authors.lastname: Davis
authors.forename: Thomas
authors.initials: T
authors.lastname: McIntosh
authors.forename: Tong-Yuan
authors.initials: TY
authors.lastname: Yang
authors.forename: Kenneth
authors.initials: K
authors.lastname: Goldberg
authors.forename: Chao
authors.initials: C
authors.lastname: Han
authors.forename: Charles
authors.initials: C
authors.lastname: Pendley
authors.forename: Hugh M
authors.initials: HM
authors.lastname: Davis
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D016466:CHO Cells / Q000378:metabolism; D002460:Cell Line; D002846:Chromatography, Affinity; D002853:Chromatography, Liquid; D006224:Cricetinae; D006031:Glycosylation; D007118:Immunoassay; D013058:Mass Spectrometry; D051379:Mice; D009844:Oligosaccharides / Q000032:analysis
chemical_list: D000911:Antibodies, Monoclonal; D009844:Oligosaccharides; C504234:siltuximab